BRAF Biomarkers
The combinations being studied in a master protocol trial were selected based on research from MSK suggesting the value of blocking KRAS mutations and ERK pathway signaling.
SABCS Clinicogenomic Study Sheds Light on HER2-Targeted Therapy Resistance
Genomic sequencing on 733 HER2-positive advanced breast cancer patients revealed mechanisms of anti-HER2 treatment resistance and potential therapeutic solutions.
Opdivo-Yervoy Before Tafinlar-Mekinist Provides Optimal Benefit to BRAF-Mutant Melanoma Patients
Premium
The Phase III DREAMseq trial pinpointed these patients' best treatment sequence, but questions linger about anti-PD-1 monotherapy and emerging treatments.Â
Day One Biopharmaceuticals Begins Phase II Trial in RAF-Altered Solid Tumors
The trial will evaluate DAY101 as a monotherapy in adult and adolescent patients with recurrent or progressive solid tumors with activating RAF alterations.
Kinnate Biopharma, Guardant Health Partner for Study of BRAF Mutations in Solid Tumors
Preliminary findings indicate that about half of the 6,000 patients with BRAF alteration-positive cancers harbored Class II and III alterations.